ACHILLES PIPELINE

Our lead product is a personalised tumour-derived T cell therapy targeting clonal cancer neoantigens. Our lead indications, advanced non-small cell lung cancer and recurrent metastatic melanoma, were selected for their high mutational burden, high level of T cell infiltration and high unmet medical need. Deaths from non-small cell lung cancer outnumber those resulting from breast cancer, colon cancer and prostate cancer combined, and there are limited approved treatment options for lung cancer and melanoma patients whose disease have not responded well to other therapies.

Achilles Pipeline

Disease

Research & Preclinical Development

Phase I/2

Pivotal

Advanced Non-Small Cell Lung Cancer

Metastatic/Recurrent Melanoma

Other Indications

An Open-Label, Multi-Centre Phase I/IIa Study Evaluating the Safety and Clinical Activity of Neoantigen Reactive T cells in Patients with Advanced Non-Small Cell Lung Cancer

An Open-Label, Multi-Centre Phase I/IIa Study Evaluating the Safety and Clinical Activity of Neoantigen Reactive T cells in Patients with Metastatic or Recurrent Melanoma